SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers

Mutations in the SMARCA4/BRG1 gene resulting in complete loss of its protein (BRG1) occur frequently in non-small cell lung cancer (NSCLC) cells. Currently, no single therapeutic agent has been identified as synthetically lethal with SMARCA4/BRG1 loss. We identify AURKA activity as essential in NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagal, Vural, Wei, Shuguang, Zhang, Wei, Brekken, Rolf A., Posner, Bruce A., Peyton, Michael, Girard, Luc, Hwang, TaeHyun, Wheeler, David A., Minna, John D., White, Michael A., Gazdar, Adi F., Roth, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253647/
https://www.ncbi.nlm.nih.gov/pubmed/28102363
http://dx.doi.org/10.1038/ncomms14098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253647/
https://www.ncbi.nlm.nih.gov/pubmed/28102363
http://dx.doi.org/10.1038/ncomms14098

Ejemplares similares